Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma
Endometrial carcinoma is comprised of two major groups: type I that is hormonally driven with a good prognosis and type II that is hormone independent with a poor prognosis. The two most common subtypes are endometrioid adenocarcinoma, the prototypic type I cancer, and uterine serous carcinoma, the...
Gespeichert in:
| Veröffentlicht in: | Future Oncology 2015-01, Vol.11 (23), p.3207-3218 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3218 |
|---|---|
| container_issue | 23 |
| container_start_page | 3207 |
| container_title | Future Oncology |
| container_volume | 11 |
| creator | Rutgers, Joanne KL |
| description | Endometrial carcinoma is comprised of two major groups: type I that is hormonally driven with a good prognosis and type II that is hormone independent with a poor prognosis. The two most common subtypes are endometrioid adenocarcinoma, the prototypic type I cancer, and uterine serous carcinoma, the prototypic type II cancer, each with their own distinct precursor lesion. The histologic type, as codified by the WHO Tumor Classification system, grade, and stage are used to guide treatment. There is an increasing interest in screening for familial risk factors, specifically Lynch syndrome. A molecular classification of endometrial cancers holds promise for future improvements in care. |
| doi_str_mv | 10.2217/fon.15.262 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1744664583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1744664583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-c4d87c538881b5f7e1884299a27dd6ec2c99f8216461ea0609798664aee756953</originalsourceid><addsrcrecordid>eNpt0E1rHCEYwHEJLdm8XfIBitBLUjobdXw9lpA0gUAuyVlc55nthBmd6njIt6_LblsoPanwex7kj9AlJWvGqLrpY1hTsWaSHaETqjhvdEvoh3rnyjRSGr5Cpzm_EcJVK8gxWjEpBBXCnCD_OnduARwDnt3yI45x-_4V58Vth7DFLnR4iiP4Mrr0F-DYYwhdnGBJgxvxVVkgDQGwj2ku-Rq7DkL0LvkhxMmdo4-9GzNcHM4z9Hp_93L70Dw9f3-8_fbU-FaypfG808qLVmtNN6JXQLXmzBjHVNdJ8Mwb02tGJZcUHJHEKKOl5A5ACWlEe4au9nvnFH8WyIudhuxhHF2AWLLdpale6LbSz__Qt1hSqL-zjClBqmp5VV_2yqeYc4LezmmYXHq3lNhdelvTWypsTV_xp8PKspmg-0N_t65A7kFflpIg-wGCB7t_1Ymh1oL_bf4FyY6Raw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275064534</pqid></control><display><type>article</type><title>Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma</title><source>MEDLINE</source><source>PubMed Central</source><creator>Rutgers, Joanne KL</creator><creatorcontrib>Rutgers, Joanne KL</creatorcontrib><description>Endometrial carcinoma is comprised of two major groups: type I that is hormonally driven with a good prognosis and type II that is hormone independent with a poor prognosis. The two most common subtypes are endometrioid adenocarcinoma, the prototypic type I cancer, and uterine serous carcinoma, the prototypic type II cancer, each with their own distinct precursor lesion. The histologic type, as codified by the WHO Tumor Classification system, grade, and stage are used to guide treatment. There is an increasing interest in screening for familial risk factors, specifically Lynch syndrome. A molecular classification of endometrial cancers holds promise for future improvements in care.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon.15.262</identifier><identifier>PMID: 26551559</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Adenocarcinoma - diagnosis ; Adenocarcinoma - etiology ; Adenocarcinoma - metabolism ; Adenocarcinoma - pathology ; Classification ; Classification schemes ; Cystadenocarcinoma, Serous ; Endometrial cancer ; endometrial carcinoma ; Endometrial Neoplasms - diagnosis ; Endometrial Neoplasms - etiology ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - pathology ; Epithelial-Mesenchymal Transition ; Female ; Females ; Genomics ; Health risk assessment ; Humans ; Medical prognosis ; molecular subtypes ; Mutation ; Neoplasm Grading ; Neoplasm Staging ; Pathology ; Precancerous Conditions ; Risk Factors ; Tumors ; uterine cancer</subject><ispartof>Future Oncology, 2015-01, Vol.11 (23), p.3207-3218</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Dec 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-c4d87c538881b5f7e1884299a27dd6ec2c99f8216461ea0609798664aee756953</citedby><cites>FETCH-LOGICAL-c362t-c4d87c538881b5f7e1884299a27dd6ec2c99f8216461ea0609798664aee756953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>313,314,780,784,792,27922,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26551559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rutgers, Joanne KL</creatorcontrib><title>Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma</title><title>Future Oncology</title><addtitle>Future Oncol</addtitle><description>Endometrial carcinoma is comprised of two major groups: type I that is hormonally driven with a good prognosis and type II that is hormone independent with a poor prognosis. The two most common subtypes are endometrioid adenocarcinoma, the prototypic type I cancer, and uterine serous carcinoma, the prototypic type II cancer, each with their own distinct precursor lesion. The histologic type, as codified by the WHO Tumor Classification system, grade, and stage are used to guide treatment. There is an increasing interest in screening for familial risk factors, specifically Lynch syndrome. A molecular classification of endometrial cancers holds promise for future improvements in care.</description><subject>Adenocarcinoma - diagnosis</subject><subject>Adenocarcinoma - etiology</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - pathology</subject><subject>Classification</subject><subject>Classification schemes</subject><subject>Cystadenocarcinoma, Serous</subject><subject>Endometrial cancer</subject><subject>endometrial carcinoma</subject><subject>Endometrial Neoplasms - diagnosis</subject><subject>Endometrial Neoplasms - etiology</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Female</subject><subject>Females</subject><subject>Genomics</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>molecular subtypes</subject><subject>Mutation</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Pathology</subject><subject>Precancerous Conditions</subject><subject>Risk Factors</subject><subject>Tumors</subject><subject>uterine cancer</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpt0E1rHCEYwHEJLdm8XfIBitBLUjobdXw9lpA0gUAuyVlc55nthBmd6njIt6_LblsoPanwex7kj9AlJWvGqLrpY1hTsWaSHaETqjhvdEvoh3rnyjRSGr5Cpzm_EcJVK8gxWjEpBBXCnCD_OnduARwDnt3yI45x-_4V58Vth7DFLnR4iiP4Mrr0F-DYYwhdnGBJgxvxVVkgDQGwj2ku-Rq7DkL0LvkhxMmdo4-9GzNcHM4z9Hp_93L70Dw9f3-8_fbU-FaypfG808qLVmtNN6JXQLXmzBjHVNdJ8Mwb02tGJZcUHJHEKKOl5A5ACWlEe4au9nvnFH8WyIudhuxhHF2AWLLdpale6LbSz__Qt1hSqL-zjClBqmp5VV_2yqeYc4LezmmYXHq3lNhdelvTWypsTV_xp8PKspmg-0N_t65A7kFflpIg-wGCB7t_1Ymh1oL_bf4FyY6Raw</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Rutgers, Joanne KL</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma</title><author>Rutgers, Joanne KL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-c4d87c538881b5f7e1884299a27dd6ec2c99f8216461ea0609798664aee756953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenocarcinoma - diagnosis</topic><topic>Adenocarcinoma - etiology</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - pathology</topic><topic>Classification</topic><topic>Classification schemes</topic><topic>Cystadenocarcinoma, Serous</topic><topic>Endometrial cancer</topic><topic>endometrial carcinoma</topic><topic>Endometrial Neoplasms - diagnosis</topic><topic>Endometrial Neoplasms - etiology</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Female</topic><topic>Females</topic><topic>Genomics</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>molecular subtypes</topic><topic>Mutation</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Pathology</topic><topic>Precancerous Conditions</topic><topic>Risk Factors</topic><topic>Tumors</topic><topic>uterine cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rutgers, Joanne KL</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rutgers, Joanne KL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma</atitle><jtitle>Future Oncology</jtitle><addtitle>Future Oncol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>11</volume><issue>23</issue><spage>3207</spage><epage>3218</epage><pages>3207-3218</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Endometrial carcinoma is comprised of two major groups: type I that is hormonally driven with a good prognosis and type II that is hormone independent with a poor prognosis. The two most common subtypes are endometrioid adenocarcinoma, the prototypic type I cancer, and uterine serous carcinoma, the prototypic type II cancer, each with their own distinct precursor lesion. The histologic type, as codified by the WHO Tumor Classification system, grade, and stage are used to guide treatment. There is an increasing interest in screening for familial risk factors, specifically Lynch syndrome. A molecular classification of endometrial cancers holds promise for future improvements in care.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>26551559</pmid><doi>10.2217/fon.15.262</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future Oncology, 2015-01, Vol.11 (23), p.3207-3218 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1744664583 |
| source | MEDLINE; PubMed Central |
| subjects | Adenocarcinoma - diagnosis Adenocarcinoma - etiology Adenocarcinoma - metabolism Adenocarcinoma - pathology Classification Classification schemes Cystadenocarcinoma, Serous Endometrial cancer endometrial carcinoma Endometrial Neoplasms - diagnosis Endometrial Neoplasms - etiology Endometrial Neoplasms - metabolism Endometrial Neoplasms - pathology Epithelial-Mesenchymal Transition Female Females Genomics Health risk assessment Humans Medical prognosis molecular subtypes Mutation Neoplasm Grading Neoplasm Staging Pathology Precancerous Conditions Risk Factors Tumors uterine cancer |
| title | Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T16%3A33%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20on%20pathology,%20staging%20and%20molecular%20pathology%20of%20endometrial%20(uterine%20corpus)%20adenocarcinoma&rft.jtitle=Future%20Oncology&rft.au=Rutgers,%20Joanne%20KL&rft.date=2015-01-01&rft.volume=11&rft.issue=23&rft.spage=3207&rft.epage=3218&rft.pages=3207-3218&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon.15.262&rft_dat=%3Cproquest_cross%3E1744664583%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275064534&rft_id=info:pmid/26551559&rfr_iscdi=true |